Gene Signature Developed for High-Risk SCC

Published: Wednesday, Oct 10, 2018
Chrysalyne Schmults, MD, MSCE

Chrysalyne Schmults, MD, MSCE

Gene expression-based biomarkers associated with disease recurrence in patients with cutaneous squamous cell carcinoma (cSCC) may help in identifying a population subset considered to have high-risk disease.

A Novel Gene Expression Signature

Researchers are currently attempting to refine existing staging systems to better distinguish between patients with low-risk disease and those with high-risk disease.3-7 Current staging systems rely on clinical features, not genetic signatures.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication